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Abstract
Background: Overexpression of Aurora A and B has been reported in a wide range of tumor types, including gastric
cancer. Anti-angiogenesis has been considered as an important therapeutic modality in advanced gastric cancer. Here
we identified a novel compound TY-011 with promising antitumor activity by targeting mitotic kinases (Aurora A and
B) and angiogenic receptor tyrosine kinase (VEGFR2).
Methods: HTRF® KinEASE™ assay was used to detect the effect of TY-011 against Aurora A, Aurora B and
VEGFR2 activities. Docking simulation study was performed to predict the binding mode of TY-011 with
Aurora A and B kinases. CCK-8 assay was used to test cell growth. Cell cycle and cell apoptosis was analyzed by flow
cytometry. Gastric cancer cell xenograft mouse models were used for in vivo study. TUNEL kit was used to determine
the apoptosis of tumor tissues. Immunohistochemistry analysis and HUVEC tube formation assay were performed to
determine the anti-angiogenesis ability. Immunofluorescence and western blot were used to test protein expression.
Results: TY-011 was identified as a potential Aurora A and B inhibitor by HTRF® KinEASE™ assay. It effectively inhibited
cellular Aurora A and B activities in a concentration-dependent manner. TY-011 occupied the ATP-binding site of both
Aurora A and B kinases. TY-011 demonstrated prominent inhibitory effects on proliferation of gastric cancer
cells. TY-011 treatment induced an obvious accumulation of cells at G2/M phase and a modest increase
of cells with >4 N DNA content, which then underwent apoptosis. Meaningfully, orally administration of
TY-011 demonstrated superior efficacy against the tumor growth in gastric cancer cell xenograft, with
~90% inhibition rate and 100% tumor regression at 9 mg/kg dose, and TY-011 did not affect the body
weight of mice. Interestingly, we observed that TY-011 also antagonized tumor angiogenesis by targeting
VEGFR2 kinase.
Conclusions: These results indicate that TY-011 is a well-tolerated, orally active compound that targets
mitosis and angiogenesis in tumor growth, and provides strong preclinical support for use as a therapeutic
for human gastric cancers.
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Background
Gastric cancer (GC) as a highly heterogeneous disease
is the fifth most common malignancies in the world
and accounts for more than half of cases annually in
East Asia [1, 2]. Unfortunately, most gastric cancers
are diagnosed in locally advanced or metastatic stage,
which is related to a poor prognosis [3]. Chemother-
apy remains the main treatment for advanced GC and
seems to have reached an efficacy plateau [4].
Multiple oncogenic signaling pathways have been
shown to regulate cancer cell survival and drug resist-
ance against chemotherapies, however, the survival
rate for patients with GC has not shown any signifi-
cant improvement yet [5, 6]. There is an urgent need
for finding new treatments and strategies to improve
outcomes.
During mitosis, the Aurora kinases are a family of
serine/threonine kinases that play crucial roles for cell
cycle control. The Aurora family has three members:
Aurora A, B and C, which are very similar within the
carboxy-terminal catalytic domain, but shows little
similarity in N-terminus [7, 8]. Aurora A and B have
attracted plenty of attention as they are closely re-
lated with occurrence of cancer. Aurora A plays an
important role in centromere duplication and matur-
ation throughout the late G2 to mitotic phases, there-
fore Aurora A inhibition delays initiation of mitosis,
which in turn causes mitotic cells accumulation [9].
In contrast, Aurora B ensures the integrity of
chromosome segregation at the spindle assembly
checkpoint (SAC) during metaphase, and executes
cytokinesis in anaphase and telophase. Aurora B
inhibition causes inactivation of the SAC and accelerates
mitotic slippage, creating polyploidy cells [10, 11]. In
addition, Aurora A has also been proposed to play a
cooperative role in cytokinesis recently [12, 13]. Therefore,
both Aurora A and B contribute to accurate chromosome
segregation during mitotic exit.
Aurora A and B are overexpressed in a wide range
of tumor types, including GC [14, 15]. Overexpression
of Aurora A has been shown to promote cell survival
through regulation of HDM2 in gastric cancer cell
lines [16], promote inflammation and tumorigenesis
by activating NF-κB through directly phosphorylation
of IκBα in mice and human gastric cancer [17]. Over-
expression of Aurora B might contribute to DNA an-
euploidy by promoting chromosomal instability in
human gastric cancers [18]. Moreover, previous study
has shown that Aurora A deletion inhibits the prolif-
eration, viability, migration and invasion of gastric
cancer cells [19]. Aurora A inhibitor MLN8237 has
been shown to induce apoptosis and autophagy of hu-
man gastric cancer cells in vitro and reduce tumor
growth in xenograft tumor model using gastric cancer
cells [16, 17, 20]. All these evidences indicated that
Aurora kinases are potential therapeutic targets in
gastric cancer.
Tumor angiogenesis has long been considered as an
attractive therapeutic target for cancer treatment [21].
VEGF is one of the most important and potent angio-
genic factors, and is closely linked with growth and
metastatic spreading of several types of tumors [22].
High levels of VEGF concentrations have been reported
to relate with vascular dissemination and poor outcomes
in patients affected by GC [23, 24]. As the major recep-
tor of VEGF, VEGFR-2 has been considered as an im-
portant therapeutic modality in advanced gastric cancer.
Apatinib, a small-molecule tyrosine kinase inhibitor that
strongly inhibits VEGFR2, has significantly improved the
median overall survival of GC patients who progressed
to at least two lines of chemotherapy compared with
placebo in a phase III clinical trial [25]. Ramucirumab, a
monoclonal antibody binding to VEGFR2, is currently
recommended in GC patients progressing after first-line
treatment [6]. Therefore, VEGFR pathways have
attracted great interest in GC therapy.
We have synthesized a series of compounds and evalu-
ated their activities against Aurora A and Aurora B ki-
nases by HTRF® KinEASE™-STK assay. A novel
compound TY-011 (Fig. 1a) was identified to have high
activity against Aurora A and B kinases, with IC50 of
about hundreds nanomole. Cell biological experiments
further confirmed that TY-011 potently inhibited cellular
activities of these two kinases. The molecular docking
analysis demonstrated that TY-011 occupied the ATP-
binding site of both Aurora A and B kinases. Import-
antly, TY-011 exhibited potential activity against gastric
cancer in vitro and in vivo. Out of expectation, we
observed that TY-011 also antagonized tumor angiogen-
esis by targeting VEGFR2 kinase. Together, these evi-
dences indicate that TY-011 works as a dual kinases
inhibitor that targets mitosis progression and angiogen-
esis, and provide strong confidence for further develop-





>98%, was synthesized by Nanjing Tianyi Bioscience Co.
Ltd, (Nanjing, Jiangsu, China). The compound was dis-
solved in DMSO as 50 mM stock solution for enzymatic
assays and cell based assays. For animal studies, TY-011
was dissolved in 5% Klucel EF + 5% ethanol +90% nor-
mal saline, the stock solution was freshly prepared every
3 days. Irinotecan was purchased from Biocompounds
Pharmaceutical Inc. (Shanghai, China) and was dissolved
in sterile water.
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Cell culture
The human GC cell lines (AGS, MGC-803, MKN-45,
SGC-7901 and SNU-16) were purchased from Cell Bank
of China Science Academy (Shanghai, China) and main-
tained in RPMI-1640 or Ham’s F-12 K medium supple-
mented with 10% FBS (PAN Biotech, Bavaria, Germany).
Human umbilical vein endothelial cell (HUVEC) ob-
tained from Allcells (Emeryville, CA, USA) were kept in
HUVEC basic medium supplemented with 10% FBS
(Allcells, Emeryville, CA, USA) and endothelial cell
growth supplements. Penicillin (100 U/ml) and strepto-
mycin (100 U/ml) were added in the medium. All these
cells were maintained in an atmosphere of 5% CO2 and
95% air at 37 °C.
Molecular modeling
X-ray protein structure of Aurora A (PDB ID: 4ZTQ)
and Aurora B (PDB ID: 4AF3) were obtained in Protein
Fig. 1 TY-011 inhibits Aurora A and Aurora B kinases activities. a Chemical structure of TY-011. b The HTRF® KinEASE™-STK kit was used to
measure inhibition of Aurora A and Aurora B activities by TY-011. The inhibition rates were determined in reference to the control. Data
presented are the mean ± SD of three independent experiments. c Effects of TY-011 on phosphorylation of Aurora A and Histone H3 were
analyzed by western blot. MGC-803 cells synchronized with nocodazole (100 nM) for 16 h were treated with various concentration of TY-011 for 24 h,
then were lysed and subjected for western blot. The results are representative of three independent experiments. d Effects of TY-011 on phosphorylation
of Aurora A and Histone H3 were analyzed by immunofluorescence. MGC-803 cells were treated with TY-011 (0.8 μM) for 24 h, then fixed and stained
for p-Aurora A (T288) (green) or p-Histone H3 (H10) (green), MPM2 (red) and DNA (blue). MPM2 was used to locate the mitotic cells. The
images are representative of two independent experiments
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Data Bank. All water molecules in the crystal structure
were removed, and then the structure was used for mo-
lecular docking using Sybyl X2. For docked structure,
energy minimization and molecular dynamic (MD)
simulation were performed using the Sander module in
Amber14. A two-step, extensive energy minimization
process based on the steepest descent method followed by
the conjugate gradient algorithm were carried out to re-
lieve bad contacts and to direct each system toward ener-
getically favorable conformations. After minimization,
each system was gently heated from 0 to 300 K in 500 ps
at constant volume and equilibrated at 300 K for another
500 ps. Finally, a 30 ns MD simulation without any restric-
tions was performed at constant pressure, and the coordi-
nates of atoms were saved every 2 ps. During the MD
simulation, all bonds involving hydrogen atoms were con-
strained using the SHAKE algorithm, and a time step of
2 fs was adopted. The temperature was controlled using
the Langevin thermostat with a collision frequency of
2.0 ps − 1. The particle mesh Ewald (PME) method was
applied to treat the long-range electrostatic interactions.
The cutoff distances for the long-range electrostatic
and van der Waals interactions were set to 12.0 Å.
Solvated interaction energy (SIE) method was used to
calculate the binding free energies between com-
pounds and Aurora A/B. For the current work, 200
snapshots extracted from the last 10 ns of MD trajec-
tory at an interval of 50 ps were used for the binding
free energy analyses.
Kinase assays
The inhibition of TY-011 on activity of Aurora A, Aurora
B and VEGFR2 was characterized by HTRF® KinEASE™-
STK/TK kit according to the manufacturer’s instructions
(Cisbio Assays, Codolet, France). Aurora A and Aurora B
were gifts from Professor Jia Li, Shanghai Institute of
Materia Medica/Chinese Academy of Sciences. VEGFR2
was purchased from Carna Biosciences (Kobe, Japan).
Cell proliferation assay
During the logarithmic growth phase, each cell line was
seeded in a 96-well tissue culture plate (Thermo Fisher
Scientific, Waltham, MA, USA) at a predetermined
density in complete medium, attached overnight and
treated with compound for the indicated time. The
medium was discarded and replaced with 10% CCK-8
(Dojindo, Kumamoto, Japan) in complete medium, then
incubated the plates for another 2 h. The OD450 was
measured with SpectraMax M5 (Molecular Devices, CA,
USA). A background absorbance of ODblank was sub-
tracted from all wells. The survival rate was determined
with following formula: Survival rate (%) = ODcompound/
ODDMSO × 100%. The IC50 values were calculated by
concentration − response curve fitting using the four
parameter method.
In VEGF-induced HUVEC proliferation assay,
HUVECs cells were seeded in a 96-well tissue culture
plate at a predetermined density in HUVEC basic
medium with 0.5% FBS. After the cells attached, cells
were treated with different concentration of TY-011 in
the presence of 50 ng/ml VEGF165 (R&D systems, Min-
neapolis, MN, USA) or 10% FBS. The CCK-8 assay as
above was used for determination of cell viability.
Cell cycle analysis
Cell cycle distribution was determined by flow cytom-
etry measurement of DNA content after cells were in-
cubated with RNase A (50 μg/ml) and propidium
iodide (50 μg/ml). The cellular DNA content was
measured on a flow cytometer (Guava EasyCyte 6HT-
2 L, Merck Millipore, Billerica, MA, USA). The per-
centage of each population was analyzed using the
InCyte software. At least 20 000 cells were analyzed
for each data point.
Apoptosis analysis
Apoptosis was detected by FITC Annexin V Apoptosis
Detection Kit I according to the manufacturer’s instruc-
tions (Dojindo, Kumamoto, Japan) to determine the
phosphatidyl serine exposure. Apoptotic cells were
quantified by a flow cytometer (Guava EasyCyte 6HT-
2 L, Merck Millipore, Billerica, MA, USA) using the
InCyte software. At least 10 000 cells were analyzed for
each data point.
Western blot
The proteins of whole cell lysates were prepared in RIPA
buffer containing protease and phosphatase inhibitors
(Thermo Fisher Scientific, Waltham, MA, USA), and
quantified by the bicinchoninic acid (BCA) method.
Immunoblotting analysis of proteins in cell lysates was
performed as previously described [26]. Primary anti-
bodies used were as follows: anti-Aurora A (#12100),
anti-p-Aurora A (Thr288) (#3079), anti-Histone H3
(#4499), and anti-p-Histone H3 (Ser10) (#9701), and
anti-cleaved caspase 3 (#9661) were purchased from Cell
Signaling Technology (Danvers, MA, USA); anti-PARP-1
(#sc-8007) and anti-GAPDH (#sc-25778) were pur-
chased from Santa Cruz (CA, USA).
Immunofluorescence
Cells were cultured on glass slides coated with 0.05 mg/ml
PDL (Sigma-aldrich, St. Louis, MO, USA) in the presence
of TY-011 (0.8 μM) or equivalent amount of DMSO for
24 h. The cells were fixed in 4% paraformaldehyde at
room temperature, then permeabilized with 0.15% Triton-
X100 and blocked in 3% BSA in PBS. The primary
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antibodies were incubated with slides at 1:100 dilution in
PBS containing 3% BSA in a wet chamber at 4 °C over-
night. The secondary antibodies Alexa Fluor H 488 goat
anti-rabbit IgG (H + L) or Alexa Fluor H 594 goat anti-
mouse IgG (H + L) (Invitrogen, Carlsbad, CA, USA) were
applied respectively for 2 h after the slides were washed
with PBS thoroughly at room temperature. After the un-
bound antibodies were removed, the slides were dried and
mounted with DAPI-fluoromount-G (Beyotime, Shanghai,
China). The images were captured with FCFM (fluores-
cence confocal microscope) (Olympus FV1000 IX81,
Tokyo, Japan) under appropriate excitation and emission
filters or phase-contrast microscope (Olympus IX73,
Tokyo, Japan). Primary antibodies used were as follows:
anti-p-Aurora A (Thr288) (#3097) and anti-p-Histone H3
(Ser10) (#9701) were purchased from Cell Signaling Tech-
nology (Danvers, MA, USA); anti-MPM2 (anti-phospho-
Ser/Thr-Pro) (#05-368) was purchased from Merck
Millipore (Billerica, MA, USA); and anti-α-tubulin (sc-
8035) was purchased from Santa Cruz (CA, USA).
HUVEC tube formation assay
HUVECs were seeded onto pre-cooled 96-well tissue
culture plate coated with Matrigel™ (BD Biosciences,
FranklinLakes, NJ). After the cells attached, the cells
were treated by various concentration of TY-011 or
equivalent amount of DMSO. The plate was incu-
bated at 37 °C, 5% CO2 humidified atmosphere for
6 h, then cell morphology was captured with a
microscopy (Olympus IX73, Tokyo, Japan).
Antitumor activity in vivo
Female BALB/c nu/nu mice (5–6 weeks, 16–18 g) were
obtained from Sino-British SIPPR/BK Lab. Animal Ltd,
Shanghai, China, with the certification number of
2008001638201. The animals were housed in specific
pathogen-free (SPF) conditions at Key Laboratory of
Brain Functional Genomics, Ministry of Education,
and were acclimatized for a week prior to use.
Human MGC-803 xenografts were established by
subcutaneously inoculating 5 × 106 cells into nude
mice. When the tumors reached a mean group size of
100 ~ 150 mm3, the mice were randomized into
control and treatment groups to receive treatment ac-
cordingly. TY-011 was orally administered at 3, 6 and
9 mg/kg once a day for 13 days. Irinotecan was intra-
peritoneally administered at 50 mg/kg twice a week
and served as positive control of this experiment. The
Fig. 2 Computational predicted binding mode of TY-011 with Aurora A and Aurora B. a Proposed binding mode of TY-011 with Aurora A in the
last snapshot of 30 ns molecular dynamic simulations. b Proposed binding mode of TY-011 with Aurora B in the last snapshot of 30 ns molecular
dynamic simulations. Bind free energies of TY-011 to Aurora A or Aurora B were calculated by the SIE method. ΔGbind is the calculated binding
free energy; ΔEvdW and ΔECoulomb are contributions of van der Waals and Coulomb interactions to ΔGbind, ΔGReaction Field and ΔGCavity describe
differences in the reaction field energy and molecular surface area upon inhibitor binding
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tumor growth was recorded with the measurement of
length (L) and width (W) by caliper every other day,
and calculated as tumor volume (V) = L ×W2/2.
Meanwhile, the body weights of mice were recorded.
The tumor volume at day n was expressed as relative
tumor volume (RTV) according to the following for-
mula: RTV% = (TVn/TV0) ×100%, where TVn is the
tumor volume at day n and TV0 is the tumor volume
at day 0. The therapeutic effect of treatment was
calculated with formula T/C (%) = mean RTV of the
treated group/mean RTV of the control group × 100%.
The tumor growth inhibition was calculated as TGI% = (1-
(mean tumor volume of the treated group on the first
day-mean tumor volume of the treated group on the end
day)/ (mean tumor volume of the control group on the
first day-mean tumor volume of the control group on
the end day)) ×100%. The inhibition rate = (1-mean
tumor weight of the treated group/ mean tumor
weight of the control group) ×100%. The tumor re-
gression of individual mouse was defined as the
tumor volume at the end was less than the tumor
volume when treatment was initiated.
Immunohistochemistry
Tumor tissues from mice were embedded in a paraf-
fin block and subjected to immunohistochemistry.
Tumor tissues were deparaffinized and hydrated, then
permeabilized with 0.5% Triton X-100/1 PBS for
10 min, hybridized with the rabbit anti-human CD31
polyclonal antibody (sc-8306; 1:200; Santa Cruz) and
an HRP-conjugated goat anti-rabbit antibody was
used as the secondary antibody. After developing
with substrate-chromogenic solution (DAB, DAKO,
Glostrup, Denmark), the sections were counterstained
with hematoxylin. Images were captured with a mi-
croscopy (Olympus IX73, Tokyo, Japan).
TUNEL histology
Apoptotic tumor tissue slides were detected by terminal
deoxynucleotidyl transferase- deoxyuridine triphosphate
nick end labeling (TUNEL) staining (DeadEnd™ Fluoro-
metric TUNEL System, Promega, Madison, WI, USA)
according to the manufacturer protocol. The slides were
observed under the fluorescence microscopy (Olympus
IX73, Tokyo, Japan).
Statistical analysis
The statistical significance of differences between groups
was evaluated by the unpaired Student’s t test and indi-
cated with ***P < 0.001, **P < 0.01, *P < 0.05. All statis-
tical tests were two sided.
Results
TY-011 inhibits activities of Aurora A and Aurora B
kinases
A series of compounds was synthesized and analyzed for
their activities against Aurora A and Aurora B kinases.
Eight of them were found to have activities against either
one of the kinases or both kinases with IC50 from
hundreds nanomole to micromole (Additional file 1:
Table S1). Of note, compound TY-011 was identified
to have the best activity against Aurora A and B
kinases, with IC50 values of 102.1 ± 10.1 nM and 93. 9 ±
33.7 nM, respectively (Fig. 1b). We then determined the
proliferation inhibitory effects of these eight compounds
against gastric cancer MGC-803 cells. Three of them
(including TY-011) exhibited potential activities against
proliferation of MGC-803 cells with IC50 values of 0.2-
0.4 μM. Considering the potential inhibitory activity
against Aurora A and B kinases as well as proliferation of
MGC-803 cells, TY-011 was therefore chosen for our fur-
ther studies.
We then determined whether TY-011 could inhibit
intracellular activities of Aurora A and Aurora B. As
Aurora kinases are expressed and active at the highest
level during G2/M phase of the cell cycle [27], MGC-
803 cells were arrested in G2/M phase by nocodazole
treatment, which was accompanied with the increased
phosphorylation of Aurora A (T288) and its total protein
Fig. 3 TY-011 suppresses the proliferation of gastric cancer cells.
Growth inhibition assays of TY-011 in vitro were performed using
the CCK-8 assay. The inhibition rates were determined in reference
to the control. The concentration–survival rate curves of TY-011 on
gastric cancer cells were drawn, and the IC50 was calculated. Data
presented are the mean ± SD of three independent experiments
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Fig. 4 (See legend on next page.)
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level. With the treatment of TY-011, the p-Aurora A
(T288) decreased in a concentration-dependent manner
(Fig. 1c). The phosphorylation of Histone H3 (S10),
which is known to be a substrate of Aurora B, was also
strongly inhibited by TY-011 in a concentration-
dependent manner (Fig. 1c). Meanwhile the total protein
levels of Aurora A and Histone H3 were not altered by
TY-011.
Moreover, Aurora kinase inhibition by TY-011 was
visualized by immunofluorescence. Phospho-Ser/Thr-
Pro Mitotic protein monoclonal #2 (MPM2) was used as
a mitotic marker (red) for labeling mitotic cells. Baseline
evaluation showed detectable levels of p-Aurora A
(T288) and p-Histone H3 (S10) in cells. In detail, the
phosphorylated Aurora A (T288) exists in the centro-
some of mitotic cells (green) and the phosphorylation of
Histone H3 (S10) was primary localized in the centro-
meres of cells during mitotic. After cells were treated
with 0.8 μM TY-011 for 24 h, the Aurora A green
foci in mitotic cells became weaker or even disap-
peared (Fig. 1d, upper panel), while the p-Histone H3
(S10) decreased sharply (Fig. 1d, lower panel). There-
fore, these results indicated that TY-011 could effect-
ively inhibit the in vitro and cellular kinase activities
of Aurora A and Aurora B.
The binding mode of TY-011 with Aurora A and Aurora B
We then conducted the molecular docking analysis
using Sybyl X2 to interpret the binding mode of TY-011
with Aurora A and B, respectively. The proposed bind-
ing modes showed that TY-011 occupied the ATP-
binding site of Aurora A and Aurora B, respectively
(Fig. 2 and Additional file 1: Figure S1). TY-011 formed
two conserved hydrogen bond with Aurora A, one was
between the nitrogen atom of pyrazole and ALA87, the
other was between the amine group of the seven-
member heterocycle and GLU85 (Fig. 2a). Similarly, TY-
011 formed two conserved hydrogen bond with Aurora
B, one was between nitrogen atom of pyrazole and
GLU109, the other was between the amine group of the
seven-member heterocycle and LYS33 (Fig. 2b). The cal-
culated binding free energy was −7.23 kcal/mol and
−8.20 kcal/mol between TY-011 and Aurora A as well as
between TY-011 and Aurora B, respectively.
TY-011 inhibits proliferation of cancer cells and induces
cell-cycle arrest and polyploidy
Given the important roles of Aurora kinases in cellular
proliferation, we then evaluated the anti-proliferation
activity of TY-011 against 5 gastric cancer cell lines.
Concentration–inhibition curves were drawn and IC50s
were calculated as shown in Fig. 3. TY-011 effectively
suppressed cell growth in a concentration-dependent
manner, with IC50 values ranging from 0.09 to 0.96 μM.
Inhibition of Aurora A induced cell cycle G2/M phase
arrest [12], while suppression on Aurora kinase B is re-
ported to cause polyploidy in cells without cytokinesis
[13]. The effects of TY-011 on cell cycle distribution was
then determined in MGC-803 and SGC-7901 cells. In
both cells, TY-011 treatment induced an obvious accu-
mulation of cells in G2/M phase and with >4 N DNA
content at 24 h, in a concentration-dependent manner
(Fig. 4a-d). In detail, the proportion of G2/M phase cells
increased from 28.8% with no treatment to 65.0%
with 0.4 μM TY-011 treatment, and the proportion of
cells with >4 N DNA content increased from 4.3 to
29.5% in MGC-803 cells (Fig. 4a and b). Similarly, the
proportion of G2/M phase cells increased from 34.0%
with no treatment to 78.6% with 1 μM TY-011 treat-
ment, and the proportion of cells with >4 N DNA
content increased from 6.7 to 14.7% in SGC-7901
cells (Fig. 4c and d).
The effects of TY-011 on cell cycle distribution at dif-
ferent time intervals were further evaluated. In both
MGC-803 and SGC-7901 cells, a significant accumula-
tion of G2/M phase cells was detected at 12 h after TY-
011 treatment (from 26.4 to 51.4% in MGC-803 cells
and from 31.6 to 45.1% in SGC-7901 cells), which in-
creased a little at the following 12 h, and then decreased
slightly at 48 h. Meanwhile, the population of cells
with >4 N DNA content started to accumulate at
24 h, albeit slightly, and increased to 39.8 and 13.9%
at 48 h in MGC-803 and SGC-7901 cells, respectively
(Fig. 4a–d).
Moreover, TY-011-induced polyploidy was further
confirmed by microscopic inspection. Compared with
control cells, chromatins of cells treated with TY-011
were not segregated properly, therefore leading to for-
mation of polyploidy (Fig. 4e). Together, these results
(See figure on previous page.)
Fig. 4 TY-011 causes accumulation of cells with ≥4 N DNA content. a MGC-803 cells were treated with indicated concentration of TY-011 for
24 h (upper panel) or with 0.2 μM TY-011 for various times (lower panel). Cell cycle distribution was assessed by flow cytometry after cells were
stained with propidium iodide. Representative data were shown. b Cell cycle proportion in (a) was quantitated. Data presented are the mean ±
SD of three independent experiments. c SGC-7901 cells were treated with indicated concentration of TY-011 for 24 h (upper panel) or with
0.5 μM TY-011 for various times (lower panel). Cell cycle distribution was assessed by flow cytometry after cells were stained with propidium
iodide. Representative data were shown. d Cell cycle proportion in (c) was quantitated. Data presented are the mean ± SD of three
independent experiments. e MGC-803 cells were treated with 0.4 μM TY-011 for 24 h, and stained with anti-α-tubulin and DAPI for
microtubules and chromosome, respectively. Scale bar, 20 μm
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showed that TY-011 induced G2/M phase arrest and
polyploidy by inhibiting Aurora A and Aurora B kinases,
thus inhibiting the proliferation of cancer cells.
TY-011 triggers apoptosis of cancer cells
We next determined the apoptotic effect of TY-011 in
MGC-803 and SGC-7901 cells. Of note, TY-011-induced
apoptosis was relatively modest at 24 h, with appropri-
ately 20–30% apoptosis in MGC-803 and SGC-7901
cells treated with the highest concentration (0.4 μM in
MGC-803 cells and 1 μM in SGC-7901 cells, respect-
ively). But an obvious increase of apoptosis was observed
in both cells at 48 h, which was in a concentration-
dependent manner. In detail, compared with 7.8% in
control cells, the apoptosis of MGC-803 cells increased
to 39.3, 78.2, and 86.1% after treated with 0.1, 0.2 and
0.4 μM TY-011, respectively. Similarly, the apoptotic
SGC-7901 cells increased from 14.1 to 17.2, 28.4 and
54.3% after treated with 0.25, 0.5 and 1 μM TY-011, re-
spectively (Fig. 5a–d). Moreover, the cleavage of
procaspase-3 and PARP-1, the apoptotic markers, were
observed at 48 h after TY-011 treatment both in MGC-
803 and SGC-7901 cells (Fig. 5e and f).
TY-011 suppresses the growth of human gastric
xenografts models
To further determine the antitumor effect of TY-011 in
vivo, we established a subcutaneous gastric carcinoma
model using MGC-803 cells. TY-011 was orally adminis-
tered at 3, 6 and 9 mg/kg once a day for 13 days for
MGC-803 tumor-bearing mice. For control tumor-
bearing mice, the same amount of vehicle was adminis-
tered on the same schedule. As shown in Fig. 6a–e and
Table 1, tumor growth was significantly inhibited by TY-
011 in a dose-dependent manner. The final TGI% of the
mice treated with 3, 6 and 9 mg/kg TY-011 were 59.41,
103.77 and 113.09%, respectively. Of note, TY-011 treat-
ment led to tumor regression, 6/8 (75%) for 6 mg/kg
group, and 8/8 (100%) for 9 mg/kg group. The average
tumor weights of TY-011-treated mice was 0.28, 0.10
and 0.09 g in 3, 6 and 9 mg/kg group, respectively,
which were significantly lower than vehicle-treated mice
(0.79 g) (Fig. 6e). Meaningfully, TY-011 did not cause
drug-related deaths or any loss in body weight of mice
(Fig. 6c). In addition, no obvious damages to vital organs
(heart, liver, spleen, lung and kidney) or any clinical
signs were observed in mice treated with TY-011 (data
not shown). These data suggested that TY-011 causes
low host toxicity at therapeutic doses.
Tumor tissues were then assayed for apoptosis using a
TUNEL kit which labels apoptotic nuclei with a fluores-
cent maker. As shown in Fig. 6f, tumor tissues from
animal receiving TY-011 (9 mg/kg) treatment showed an
obvious increase in apoptosis. These findings coincided
with the apoptotic effect of TY-011 in vitro, highlighting
the involvement of apoptosis in the tumor growth in-
hibitory effects exerted by TY-011 in vivo.
TY-011 antagonizes the angiogenesis of human
endothelial cells
Interestingly, we observed a significant decreased blood
vessel density in tumors from TY-011 treated mice
(Fig. 7a), indicating TY-011 might suppress the blood
vessel formation. So the tumor tissues were used for im-
munohistochemistry to visualize the human angiogenesis
maker CD31. As shown in Fig. 7b, the CD31 staining in
TY-011 treated group was much less than control group,
suggesting the vascularization in tumors was inhibited.
Then a series of experiments was performed to demon-
strate the effects of TY-011 on angiogenesis. Since the
activation of VEGFR2 is overwhelmingly regarded as the
most critical driver of tumor angiogenesis [28], we first
determined the activity of TY-011 against VEGFR2 in
vitro. The result showed that TY-011 effectively inhib-
ited the activation of VEGFR2 in a concentration-
dependent manner, with IC50 of 103.4 ± 6.2 nM (Fig. 7c).
To address the specificity of TY-011 antagonizing the
endothelial cell growth stimulated by VEGF, HUVECs
were exposed to two different stimuli, VEGF and FBS,
under the treatment of TY-011 for 72 h. Under these
two different culture conditions, HUVECs showed dif-
ferent response to TY-011. The IC50 value in cells
treated with VEGF were 13-fold lower than in cells
treated with FBS; suggesting TY-011 antagonized the
HUVECs growth driven by VEGF more potent than by
FBS (Fig. 7d). HUVEC tube formation assay were
performed to evaluate the effect of TY-011 on tube
formation. In DMSO treated group, intact tube
meshes was formed. However, these tube meshes were
disturbed after exposure to TY-011 for 6 h (Fig. 7e
and f ). TY-011 didn’t affect HUVEC proliferation
under this treatment condition (Fig. 7g), indicating
(See figure on previous page.)
Fig. 5 TY-011 induces apoptosis. a and b MGC-803 and SGC-7901 cells were treated with indicated concentration of TY-011 for 48 h. Apoptosis
was assessed by flow cytometry after Annexin V/PI staining. Representative images were shown. c and d Quantitation of apoptotic cells
in a and b. Data presented are the mean ± SD of three independent experiments. e MGC-803 cells were treated with various concentration
of TY-011 for the indicated time. f SGC-7901 cells were treated with various concentration of TY-011 for 48 h. Cells in (e and f) were lysed
and subjected for western blot to determine the protein levels of cleaved caspase-3 and PARP-1. The results are representative of three
independent experiments
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that the effect of TY-011 to antagonize the angiogen-
esis was not resulted from its toxic effect on HUVEC
cells. Together, these results demonstrated that TY-
011 had anti-angiogenesis potential.
Discussion
In the present study, we reported a well-tolerated and
orally active small molecule TY-011 for gastric cancer
treatment via targeting mitosis pathways and angiogenesis.
Fig. 6 TY-011 suppresses tumor growth in vivo. MGC-803 xenograft bearing nude mice were treated with TY-011 as indicated schedule,
respectively. a and b The tumor volume and RTV were recorded and plotted against days post inoculation. Data presented are the mean
± SEM (n = 8). c Relative body weight of mice. d The pictures of tumors (e) Tumor weights. Data presented are the mean ± SEM (n = 8).
f The tumors were harvested and subjected for TUNEL staining to evaluate the apoptosis. Representative images are shown. Scale bar, 50 μm
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:183 Page 11 of 15
TY-011 effectively suppressed the activities of Aurora A,
Aurora B and VEGFR2 kinases in vitro, inhibited cancer
cell proliferation by disturbing mitotic progression and
inducing apoptosis, and more importantly, abrogated
tumor growth of gastric xenograft model in vivo without
any obvious toxicity.
The kinase assay clearly showed that TY-011
concentration-dependently inhibited Aurora A and Aur-
ora B kinases in vitro, with IC50 of about hundreds
nanomole. Consistently, TY-011 also effectively inhibited
the intracellular activities of Aurora A and Aurora B
kinases, as evidenced by the decreased phosphorylation
of Aurora A (T288) and Histone H3 (S10) in TY-011-
treated MGC-803 cells. The molecular docking analysis
demonstrated that TY-011 occupied the ATP-binding
site of both Aurora A and B kinases. These results indi-
cated that TY-011 is a potent and novel pan Aurora A/B
kinase inhibitor.
In line with previously reported pan kinase inhibitors
of Aurora A and Aurora B, TY-011 induced an obvious
accumulation of cells in G2/M phase and with >4 N
DNA content, in a concentration-dependent manner.
However, the increase of cells with >4 N DNA content
was relatively modest, which might be related with the
expression of wild-type p53 in MGC-803 and SGC-7901
cells. It has been reported that whether cells with mitotic
defects to be arrested with 4 N DNA content in pseudo-
G1 or endoreduplicate with the accumulation of >4 N
DNA content depends on the integrity of the p53-
dependent postmitotic checkpoint [29]. With the normal
function of p53 in both MGC-803 and SGC-7901 cells,
the postmitotic checkpoint ensured that most cells with
mitotic errors were arrested in tetraploid status.
Importantly, TY-011-treated cells with prolonged mi-
totic arrest or continued proliferation with cytokinesis
failure subsequently underwent apoptosis. Interestingly,
TY-011 mainly accumulated cells in G2/M phase and
with >4 N DNA content within the first 24 h of treat-
ment, and then induced apoptosis at 48 h. Previous
studies have demonstrated that cell death after Aurora A
inhibition–mediated mitotic arrest requires activation of
proapoptotic pathways [30]. In consistence, here we did
not observe the cleavage of procaspase 3 and PARP at
24 h, indicating the activation of proapoptotic pathways
happened in the following 24 h, which triggered cell
undergo apoptosis. Meaningfully, TY-011-induced apop-
tosis was also observed in tumor tissues, as evidenced by
an increase of TUNEL staining, which is a marker of
apoptosis. Therefore, by inducing G2/M phase arrest,
polyploidy and apoptosis, TY-011 exhibited its antitumor
activity in vitro and in vivo.
Interestingly, we have noticed that tumors in TY-011-
treated mice had lower blood vessel density than control
group, which was further confirmed by the immunohis-
tochemistry analysis of CD31 maker. Given the import-
ant role of VEGFR2 in tumor angiogenesis, we first
determined the activity of TY-011 against VEGFR2 kin-
ase. We found that TY-011 was able to inhibit the
VEGFR2 kinase with IC50 of about hundreds nanomole,
effectively inhibit VEGF-stimulated HUVEC cells prolif-
eration and suppress the tube formation of HUVEC
cells. These data indicated that TY-011 was able to
antagonize tumor angiogenesis. Therefore, TY-011
exhibited efficient antitumor effect by targeting mitotic
kinases (Aurora A and B) and angiogenic receptor tyro-
sine kinase (VEGFR2). As mitosis of cancer cells and
angiogenesis by endothelial cells are two key steps of
tumorigenesis, we believe that the therapeutic strategy
of targeting these two types of cells should be of import-
ant value for cancer therapy. Actually, the synergistic
antitumor effects of combined inhibition of Auroras
and VEGFRs have been receiving much attention.
Dual inhibitors of these two types of kinases, such as
ENMD-2076, ABT-348, and JNJ-28840172, have been
reported recently to exhibit potential antitumor activ-
ities in different cancer types [31–33]. Meaningfully,
ENM-2076 is currently in Phase I/II clinical trials for
several types of cancer [34], which greatly encouraged
the development of this type of dual inhibitors. Here
we have demonstrated TY-011 exhibited a significant
antitumor effect in gastric cancer xenograft model at
a very low dose, and showed no observable side
effects, therefore TY-011 deserves further investigation
and development.
Table 1 In vivo efficacy of TY-011 against human MGC-803 xenograft
Compound Body weight (g) Tumor volume (mm3) T/C (%) TGI (%) Tumor
weight (g)
Inhibition
rate (%)Start End Start End
Control 22.1 ± 0.2 22.6 ± 0.2 190.4 ± 6.2 783.7 ± 22.7 / / 0.79 ± 0.07 /
TY-011 (3 mg/kg) 20.8 ± 0.1 21.8 ± 0.1 192.8 ± 7.1 433.6 ± 16.2*** 54.55 59.41 0.28 ± 0.02*** 64.9
TY-011 (6 mg/kg) 20.9 ± 0.1 20.3 ± 0.2 191.2 ± 6.2 168.8 ± 7.1*** 21.82 103.77 0.10 ± 0.01*** 87.7
TY-011 (9 mg/kg) 21.4 ± 0.1 21.7 ± 0.1 189.0 ± 4.9 111.4 ± 3.6*** 14.53 113.09 0.09 ± 0.01*** 89.0
Irinotecan (50 mg/kg) 21.2 ± 0.2 21.4 ± 0.2 191.7 ± 6.7 59.3 ± 6.5*** 8.04 122.31 0.03 ± 0.01*** 96.2
The body weight, tumor volume, T/C values, TGI, tumor weight, and inhibition rate were used to evaluate the tumor response to TY-011 treatment
Data presented are the mean ± SEM. ***p < 0.001 vs. control
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Fig. 7 TY-011 antagonizes the angiogenesis. a Representative images of tumor tissues. b The tumors tissue were sectioned and subjected for
immunohistochemistry of CD31 (angiogenesis marker) staining. White arrow means blood vessel. Representative images were shown. Scale bar,
50 μm. c The HTRF® KinEASE™-TK kit was used to measure inhibition of VEGFR2 by TY-011. The inhibition rates were determined in reference
to the control. Data presented are the mean ± SD of three independent experiments. d Growth inhibition effects of TY-011 on HUVECs in
the presence or absence of VEGF were determined by CCK-8 assay. Data presented are the mean ± SD of three independent experiments.
e HUVECs grown on MatrigelTM were treated with various concentration of TY-011 or equivalent DMSO for 6 h. Representative images from three
independent assays are shown. f Quantitation of tube formation in (e). Data presented are the mean ± SD of three independent experiments.
g HUVECs cells were treated with various concentration of TY-011 for 6 h, and growth inhibition was determined by CCK-8 assay
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Although the synergistic antitumor effects of targeting
Auroras and VEGFRs kinases have been noticed, the
mechanism is unclear. Previous studies have demon-
strated controlling vascularization of neoplasms by
VEGFR inhibition can induce tumor shrinkage, thus
causing hypoxic conditions in the tumor environment.
Hypoxia stimulates Aurora activity and consequently in-
creases the malignant potential of hepatoma cells [35].
In addition, Aurora A inhibition has been observed to
decrease the VEGF transcription and secretion in neuro-
blastoma cells and inhibit the HUVECs tubule formation
[36]. So there might be a feedback loop of Aurora-
VEGF-VEGFRs, we presumed that the mechanisms of
Auroras and VEGFRs kinases dual inhibitors may be
related with cutting off this feedback loop. Besides these
three kinases, we could not exclude the possibility that
TY-011 might have activities against other kinases or
might directly target proteins involved in tumor devel-
opment. Given the impressive antitumor activity of TY-
011 in vivo, better understanding of the mechanisms
would definitely beneficial for its development and
future application in clinic, and therefore these studies
will be performed in our further research work.
Conclusions
Our study demonstrates that TY-011 is a novel, orally
active kinase inhibitor with a mechanism of action that
includes inhibition of kinases involved in both mitosis
(Aurora A and B) and angiogenesis (VEGFR2). TY-011
exhibits promising antitumor activity both in vitro and
in vivo against gastric cancer, and is worthy for further
development as a therapeutic approach in gastric cancer.
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